LITERATURVERZEICHNIS

1 Braunwald E, Hauci AS, Kasper DL, et al.: Harrisons Innere Medizin Band 1 (deutsche Auflage in Zusammenarbeit mit der Charité). Mc Graw-Hill ABW Wissenschaftsverlag GmbH. 2003; 1451-1456 .

2 Statistisches Bundesamt Deutschland: Sterbefälle nach den 10 häufigsten Todesursachen 2001.

Francis GS: Am J Med. 2001; 110(7A): 37S-46S

4 Ho KKL, Anderson KM, Kannel WB, et al.: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993; 88: 107-115.

5 Ho KKL, Pinsky JL, Kannel WB, et al.: The epidemiology of heart failure. The Framingham Study. J Am Coll Cardiol.1993; 22: 6A-13A.

6 Braunwald E, Zipes DP, Libby P: Heart Disease: A Textbook of Cardiovascular Medicine (6th Edition) . W.B. Saunders Company. Philadelphia, London, New York, St. Louis, Sydney, Toronto. 2001; 503-533.

7 ter Keurs HE: Heart failure and Starling´s Law of the Heart. Can J Cardiol. 1996; 12(10): 1047-1057.

8 Grossman W, Jones D, McLaurin LP: Wall stress patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975; 56 56-5664.

9 Anversa P, Ricci R, Olivetti R: Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review. J Am Coll Cardiol. 1987; 7: 1140-1149.

10 St. John Sutton MG, Sharpe N: Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation. 2000; 101: 2981-2988.

11 Piano MR, Bondmass M, Schwertz DW: The molecular and cellular pathophysiology of heart failure. Heart Lung. 1998; 27:3-19.

12 Morkin E: Postnatal muscle fiber assembly: localisation of newly synthesized myofibrillar proteins. Science. 1970; 167: 1499-1501.

13 Gerdes AM, Campbell SE, Hilbelink DR: Structural remodeling of cardiac myocytes in rats with ateriovenous fistulas. Lab Invest. 1988; 59 857-59861 .

14 Kannel WB, Gordon T, Offutt D: Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the framingham study. Ann Intern Med. 1969; 71: 89-105.

15 Levy D, Garrison RJ, Savage D, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561-1566.

Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001; 141: 334-341.

17 Sussman MA, McCulloch A, Borg TK: Dance Band on the Titanic: Biomechanical Signaling in Cardiac Hypertrophy. Circ Res. 2002; 91: 888-898.

18 Log CS, Kariya K, Karns L, et al.: Sympathetic activity: modulator of myocardial hypertrophy. J Cardiovasc Pharmacol. 1991; 17(suppl2): S20-S24.

19 Simpson PC, Kariya K, Karns LR, et al.: Adrenergic hormones and control of cardiac myocyte growth. Mol Cell Biochem. 1991; 104: 35-43.

20 Parker TG, Packer SE, Schneider MD: Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest. 1990; 85: 507-514.

21 Parker TG, Chow KL, Schwartz RJ, et al.: Positive and negative control of the skeletal alpha-actin promoter in cardiac muscle. A proximal serum response element is sufficient for induction by basic fibroblast growth factor (FGF) but not for inhibition by acidic FGF. J Biol Chem. 1992; 267: 3343-3350.

22 Ito H, Hiroe M, Hirata Y, et al.: Insulin-like growth factor-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993; 87: 1715-1721.

23 Lavandero S, Foncea R, Pérez V, et al.: Effect of inhibitors of signal transduction on IGF-1-induced protein synthesis associated with hypertrophy in cultured neonatal rat ventricular myocytes. FEBS Lett. 1998; 422: 193-196.

24 Ebensperger R, Acevedo E, Melendez, et al.: Selective increase in cardiac IGF-1 in rat model of ventricular hypertrophy. Biochem Biophys Res Commun. 1998; 243: 20-24.

25 Sugden PH, Fuller SJ: Regulation of protein turnover in skeletal and cardiac muscle. Biochem J. 1991; 273: 21-37.

26 Hannan RD, Rothblum LI: Regulation of ribosomal DNA transcription during neonatal cardiomyocyte hypertrophy. Cardiovasc Res. 1995; 30: 501-510.

27 Sutton MG, Sharpe N: Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25): 2981-2988.

28 Cameron VA, Ellmers LJ: Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology. 2003; 144(6): 2191-2194.

29 Calderone A, Takahashi N, Izzo NJ Jr, et al.: Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocytes phenotypes and differential induction of peptide growth factor mRNAs. Circulation. 1995; 92: 2385-2390.

30 Frey N, Olson EN: Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol. 2003; 65 45-6579.

31 Jalili T, Takeishi Y, Walsh RA: Signal transduction during cardiac hypertrophy: the role of Gαq, PLC β I, and PKC. Cardiovasc Res. 1999; 44: 5-9.

32 Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J Mol Med. 1998; 76 : 725-746.

33 Simpson PC: Beta-PKC and hypertrophic signaling in human heart failure. Circulation. 1999; 99: 334-337.

34 Disatnik MH, Buraggi G, Mochly-Rosen D: Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res. 1994; 210: 287-297.

35 Bowling N, Walsh RA, Song G, et al.: Increased protein kinase C activity and expression of Ca-sensitive isoforms in the failing human heart. Circulation. 1999; 99: 384-391.

36 Kerkelä R, Ilves M, Pikkarainen S, et al.: Identification of PKCα isoform specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides. Mol Pharmacol. 2002; 62: 1482-1492.

37 Gu X, Bishop SP: Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res.1994; 75: 926-931.

38 Walsh MP, Horowitz A, Clément-Chomienne O, et al.: Protein kinase C mediation of Ca2+-independent contractions of vascular smooth muscle. Biochem Cell Biol. 1996; 74: 485-502.

39 Castagna M, Takai Y, Kaibuchi K, et al.: Direct activation of calcium-activated, phopholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982; 257: 7847-7851.

40 Pucéat M, Vassort G: Signalling by protein kinase C isoforms in the heart.Mol Cell Biochem. 1996; 157: 65-72.

41 Brutsaert DL: Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003; 83: 59-115.

42 Parodi O, DeMaria R, Oltrona L, et al.: Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation. 1993; 88: 509-522.

43 Opherk D, Schwartz F, Mall G, et al.: Coronary dilatory capacity in idiopathic dilated cardiomyopathy: analysis of 16 patients. Am J Cardiol. 1983; 51: 1657-1662.

44 Nitenberg A, Foult JM, Blanchet F, et al.: Multifactorial determinants of reduced coronary flow reserve after dipyridamol in dilated cardiomyopathy. Am J Cardiol. 1985; 55: 748-754.

45 Traverse JH, Melchert P, Pierpont GL, et al.: Regulation of myocardial blood flow by oxygen consumption is maintained in the failing heart during exercise. Circ Res. 1999; 84: 401-408.

46 Spinale FG, Tanaka R, Crawford FA, et al.: Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation. 1992; 85: 717-729.

47 Shannon RP, Komamura K, Shen Y, et al.: Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure.Am J Physiol. 1993; 265: H801-H809.

48 Anversa P, Olivetti G, Melissari M, et al.: Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat. J Mol Cell Cardiol. 1980; 12: 781-795.

49 Davis D, Baily R, Zelis R: Abnormalities in systemic norepinephrine kinetics in human congestive heart failure. Am J Physiol. 1988; 254: E760-E766.

50 Hasking GJ, Esler MD, Jennings GL, et al.: Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986; 73: 615-620.

51 Rodeheffer RJ, Lerman A, Heublein DM, et al.: Increased plasma concentration of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992; 67 : 719-724.

52 Margulies KF, Hildebrand FL Jr, Lerman A, et al.: Increased endothelin in experimental heart failure. Circulation. 1990; 82: 2226-2230.

53 Wei CM, Lerman A, Rodeheffer RJ, et al.: Endothelin in human congestive heart failure. Circulation. 1994; 89: 1580-1586.

54 Dzau VJ, Colucci WS, Hollenberg NK, et al.: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981; 93 : 645-651.

55 Goldsmith SR, Francis GS, Cowley AW, et al.: Increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol. 1983; 1: 1385-1390.

56 Heart Disease. A Textbook of Cardiovascular Medicine 5th Ed. Philadelphia W.B. Saunders Company. 1996; 394-420.

57 Atlas SA, Kleinert HD, Camargo MJ, et al.: Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature. 1984; 309: 717-719.

58 Marcus LS, Hart D, Packer M, et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled randomized crossover trail. Circulation. 1996; 94: 3184-3189.

59 Melo LG, Veress AT, Ackerman U, et al.: Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Regul Pept. 1999; 79: 109-115.

60 Silberbach M, Gorenc T, Hershberger RE, et al.: Extracellular signal-regulated protein kinase activation is required for the antihypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J Biol Chem. 1999; 274(35): 24858-24864.

61 Horio T, Nishikimi T, Yoshihara F, et al.: Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 2000; 35(1): 19-24.

62 Calderone A, Thaik CM, Takahashi N, et al.: Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998; 101(4): 812-818.

63 N akaoka H, Imitaka K, Amano M, et al.: Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med. 1985; 313: 892-893.

64 Tikkanen J, Fyhrquist F, Metsarinne K, et al.: Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy subjects. Lancet. 1985; ii : 66-69.

65 Burnett Jr JC, Kao PC, Hu DC, et al.: Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986; 231: 1145-1147.

66 Clerico A, Iervasi G, Del Chicca MG, et al.: Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric essay in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 1998; 21: 170-179.

67 Wijbenga JAM, Balk AHMM, Jonkman FAM, et al.: Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure. Eur J Hear Failure. 1999; 1: 51-58.

68 Habib F, Dukta D, Crossman D, et al.: Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet. 1994; 344: 371-373.

69 Kitamura K, Kangawa K, Kawamoto M, et al.: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993; 192: 553-560.

70 Kobayashi K, Kitamura K, Etoh T, et al.: Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J. 1996; 131: 994-998.

71 Nishikimi T, Saito Y, Kitamura K, et al.: Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995; 26: 1424-1431.

72 Cheng C-P, Onishi K, Othe N, et al.: Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol. 1998; 31: 1679-1686.

73 Dzau VJ, Packer M, Lilly LS, et al.: Prostaglandins in severe congestive heart failure. N Engl J Med. 1984; 310: 347-352.

74 Kirsch B: Electron microscopy of the atrium of the heart. Exp Med Surg. 1956; 14: 99-111.

75 de Bold AJ, Borenstein HB, Veress AT, et al.: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981; 8: 89-94.

76 Kangawa K, Matsuo H: Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun. 1984; 118: 131-139.

77 Flynn TG, de Bold ML, de Bold AJ: The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun. 1983; 117: 859-865.

78 Sudoh T, Kangawa K, Minamino N, et al.: A new natriuretic peptide in porcine brain. Nature. 1988; 332: 78-81.

79 Kambayashi Y, Nakao K, Mukoyama M, et al.: Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. 1990; 259: 341-345.

80 Schulz-Knappe P, Forssmann K, Herbst F, et al.: Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr. 1988; 66 : 752-759.

81 Totsune K, Takahashi K, Murakami O, et al.: Natriuretic peptides in the human kidney. Hypertension. 1994; 24: 758-762.

82 Meyer M, Richter R, Brunkhorst, et al.: Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am J Physiol. 1996; 271: F489-F497.

83 Sudoh T, Minamino N, Kangawa K, et al.: C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990; 168: 863-870.

84 Brown J, Zuo Z: C-type natriuretic peptide and atrial natriuretic peptide receptors of rat brain. Am J Physiol. 1993; 264: R513-R523.

85 Ueda S, Minamino N, Aburaya M, et al.: Distribution and characterization of immunoreactive porcine C-type natriuretic peptide. Biochem Biophys Res Commun. 1991; 175: 759-767.

86 Komatsu Y, Nakao K, Suga S, et al.: C-type natriuretic peptide (CNP) in rats and humans. Endocrinology. 1991; 129: 1104.

87 Banks M, Wei C-M, Kim Ch, et al.: Mechanism of relaxations to C-type natriuretic peptide in veins. Am J Physiol. 1996; 271: H1907-H1911.

88 Schweitz H, Vigne P, Moinier D, et al.: A new member of the natriuretic peptide family is present in the venom of the green mamba (dendroaspis angusticeps). J Biochem. 1992; 267: 13928-13932.

89 Schirger JA, Heublein DM, Chen HH, et al.: Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 1999; 74: 126-130.

90 Inagami T, Misono Ks, Fukumi H, et al.: Structure and physiological actions of rat atrial natriuretic factor. Hypertension. 1987; 10(5): 1113-1117.

91 Nakao K, Ogawa Y, Suga S, et al.: Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992; 10: 1111-1114.

92 Itoh H, Sagawa N, Hasegawa M, et al.: Expression of biologically active receptors for natriuretic peptides in the human uterus during pregnancy. Biochem Biophys Res Commun. 1994; 203: 206-207.

93 Boomsma F, Wijbenga A, Jonkman F, et al.: Neurohormonal activation adressed and at peak exercise in patients with congestive heart failure (NYHA class 1-3). J Hypertens. 1998; 16(suppl 2): S230, (Abstract).

94 Konrad EM, Thibault G, Schiffrin EL, et al.: Atrial natriuretic factor receptor subtypes in the rat central nervous system. Hypertension. 1991; 17: 1144-1151.

95 Drewett JG, Garbers DL: The family of guanylyl cyclase receptors and their ligands. Endocr Rev. 1994; 15(2): 135-162.

96 Maack T, Suzuki M, Almeida FA, et al.: Physiological role of silent receptors of atrial natriuretic factor. Sience. 1987; 238: 675-678.

97 Wilcox JN, Augustine A, Goeddel DV, et al.: Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol. 1991; 11(7): 3454-3462.

98 Hollister AS, Rodeheffer RJ, White FJ, et al.: Clearance of natriuretic factor by lung, liver, and kidney in human subjects and the dog. J Clin Invest. 1989; 83(2): 623-628.

99 Cerra MC: Cardiac distribution of the binding sites for natriuretic peptides in vertebrates. Cardioscience. 1994; 5(4): 215-224.

100 Matsukawa N, Grzesik WJ, Takahashi N, et al.: The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA. 1999; 96(13): 7403-7408.

101 Schulz S, Singh S, Bellet RA, et al: The primary structure of a plasma membane guanylate cyclase demonstrates diversity within this new receptor family. Cell. 1989; 58: 1155-1162.

102 Tremblay J, Desjardins R, Hum D, et al.: Biochemistry and physiology of the natriuretic peptide receptor guanylyl cylases. Mol Cell Biochem. 2002; 230: 31-47.

103 Koller KJ, Lowe DG, Bennett GL: Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991; 252: 120-123.

104 Hirata Y, Emori T, Ohta K, et al.: Vasoconstrictor-induced heterologous down-regulation of vascular atrial natriuretic peptide receptor. Eur J Pharmacol. 1989; 164: 603-606.

105 Misono KS: Atrial natriuretic factor binding to its receptor is dependent on chloride concentration: A possible feedback-control mechanism in renal salt regulation. Circ Res. 2000; 86: 1135-1139.

106 Anand-Srivastava MB: Atrial natiuretic peptide-C receptor and membrane signalling in hypertension. J Hypertens. 1997; 15: 815-826.

107 Suga S, Nakao K, Hosoda K, et al.: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992; 130(1): 229-239.

108 Nussenzveig DR, Lewicki JA, Maack T: Cellular mechanism of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem. 1990; 265: 20952-20958.

109 Matsukawa N, Grzesik WJ, Takahashi, et al.: The natriuretic peptide clearance receptor locally modulates the physiological effects of natriuretic peptide system. Proc Natl Acad Sci USA. 1999; 96: 7403-7408.

110 Kashiwagi M, Katafuchi T, Kato A, et al.: Cloning and properties of a novel natriuretic peptide receptor, NPR-D. Eur J Biochem. 1995; 233: 102-109.

111 Ravichandran LV, Johns RA: Upregulation of endothelial nitric oxide synthase expression by cyclic guanosine 3´-5´monophosphate. FEBS Lett. 1995; 374: 295-298.

112 Marin-Grez M, Fleming JT, Steinhausen M: Atrial natriuretic peptide causes pre-glomerular vasodilation and post-glomerular vasoconstriction in rat kidney. Nature. 1986; 324: 473-476.

113 Sonnenberg H, Honrath U, Chong CK, et al.: Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol. 1986; 250: F963-F966.

114 McMurray J, Seidelin PH, Struthers AD: Evidence for a proximal and distal nephron action of atrial natriuretic factor in man. Nephron. 1989; 51: 39-43.

115 Dillingham MA, Anderson RJ: Inhibition of vasopressin action by atrial natriuretic factor Science. 1986; 231: 1572-1573.

116 Volpe M, Odell G, Kleinert HA, et al.: Effect of atrial natriuretic factor (ANF) on blood pressure, renin and aldosterone in Goldblatt hypertension. Hypertension. 1985; 7(suppl 1): 43-48.

117 Cuneo RC, Espiner EA, Nicholls MG, et al.: Effect of physiological levels of atrial natriuretic peptide on hormone secretion: Inhibition of angiotensin-induced aldosterone secretion and renin release in normal man. J Clin Endocrinol Metab. 1987; 65: 765-772.

118 Pfaffendorf M: Atriales natriuretisches peptid als angiotensin-II-antagonist. Med Mol Pharm. 1992; 15: 169-178.

119 Levin ER, Gardner DG, Samson WK: Mechanisms of disease: natriuretic peptide. N Engl J Med. 1998; 339: 321-328.

120 Calderone A: The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial inducible nitric oxide synthase Heart Failure. Reviews. 2003; 8: 55-70.

121 Wijeyaratne CN, Moult PJA: The effect of alpha human atrial natriuretic peptide on plasma volume in vascular permeability in normotensive subjects. J Clin Endocrinol Metab. 1993; 76: 343-346.

122 Morishita R, Gibbons GH, Pratt RE, et al.: Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest. 1994; 94(2): 824-829.

123 Hutchinson HG, Trindade PT, Cunanan DB, et al.: Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc Res. 1997; 35(1): 158-167.

124 Suhasini M, Li H, Lohmann SM, et al.: Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway. Mol Cell Biol. 1998; 18(12):6983-6994.

125 Cao L, Gardner DG: Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995; 25: 227-234.

126 Redondo J, Bishop JE, Wilkins MR, et al.: Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen sythesis by adult cardiac fibroblasts. J Pharmacol. 1998; 124(7): 1455-1462.

127 Sengenes C, Berlan M, De Glisezinski I, et al.: Natriuretic peptides: A new lipolytic pathway in human adipocytes. FASEB J. 2000; 14: 1345-1351.

128 Sugimoto T, Kikkawa R, Haneda M, et al.: Atrial natriuretic peptide inhibits endothelin-1-induced activation of mitogen-activated protein kinase in cultured rat mesangial cells. Biochem Biophys Res Commun. 1993; 195(1): 72-78.

129 Isono M, Haneda M, Maeda S, et al.: Atrial natriuretic peptide inhibits endothelin-1-induced activation of JNK in glomerular mesangial cells. Kidney Int. 1998; 53(5): 1133-1142.

130 Biesiada E, Razandi M, Levin VER: Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J Biol Chem. 1996; 271(31): 18576-18581.

131 Hu RM, Levin ER: Astrocyte growth is regulated by neuropeptides through Tis8 and basic fibroblast growth factor. J Clin Invest. 1994; 93(4): 1820-1827.

132 Anand-Srivastava MB, Srivastava AK, Cantin M: Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cylase/cAMP signal transduction system. J Biol Chem. 1990; 265: 8566-8572.

133 J ohnson BG, Trachte GJ, Drewett JG: Neuromodulatory effect on the atrial natriuretic factor clearance receptor binding peptide, cANF(4-23)-NH_2 in rabbit isolated vasa deferentia. J Pharmacol Exp Ther. 1991; 256: 720-726.

134 Maki M, Takayanagi R, Misono KS, et al.: Structure of rat atrial natriuretic factor precursor deduced from cDNA sequence. Nature. 1984; 309: 222-224.

135 Seidman CE, Duby AD, Choi E: The structure of rat preproatrial natriuretic factor as defined by complementary DNA clone. Science. 1984; 225: 324-326.

136 Yamanaka M, Greenberg B, Johnson L, et al.: Cloning and sequence analysis of the cDNA for the rat atrial natriuretic factor precursor. Nature. 1984; 309: 719-722.

137 Zivin RA, Condra JH, Dixon RAF, et al.: Molecular cloning and characterization of DNA sequences encoding rat and human atrial natriuretic factors. Proc Natl Acad Sci USA. 1984; 81: 6325-6329.

138 Oikawa S, Imai M, Ueno A, et al.: Cloning and sequence analysis of cDNA encoding precursor for human atrial natriuretic polypeptide. Nature. 1984; 309: 724-726.

139 Voulteenaho O, Arjamaa O, Ling N: Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun. 1985; 129: 82-88.

140 Day ML, Schwartz D, Wiegand RC, et al.: Ventricular atriopeptin unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone. Hypertension. 1987; 9: 485-491.

141 Stockmann PT, Will DH, Sides SD, et al.: Reversible induction of right ventricular atriopeptin synthesis in hypertrophy due to hypoxia. Circ Res. 1988; 63: 207-213.

142 Newman TM, Severs NJ: Arrested exocytosis of atrial secretory granules. J Mol Cell Cardiol. 1990; 22: 771-786.

143 Gilloteaux J, Jennes L, Menu R, et al.: Ultrastructural immunolocalization of the atrial natriuretic factor pathway in fetal neonatal and adult Syrian hamsters: from the atrial cardiomyocytes in the circulation via the endocardium, atrial capillaries and epicardium. J Submicrosc Cytol Pathol. 1991; 23: 75-91.

144 Yan W, Wu F, Morser J, et al.: Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. PNAS. 2000; 97: 8525-8529.

145 Vesely DL: Atrial natriuretic peptides in pathological diseases. Cardiovasc Res. 2001; 51: 647-658.

146 Vesely DL: Atrial natriuretic peptides in the diagnosis and treatment of congestive heart failure. CHF. 1999; 5: 171-179,183.

147 Vesely DL: Congestive heart failure update: new cardiac peptides in diagnosis and treatment. Consultant. 2000; 40: 253-263.

148 Nemer M, Lavigne JP, Droun J, et al.: Expression of atrial natriuretic factor gene in heart ventricular tissue. Peptides. 1986; 7: 1147-1152.

149 Ruskoaho H, Thölken H, Lang RE: Increase in atrial pressure releases atrial natriuretic peptide from isolated perfused rat hearts. Pflugers Arch. 1986; 407: 170-174.

150 de Bold AJ, Bruneau BG, Kursoki de Bold ML: Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996; 31: 7-18.

151 Laine M, Arjamaa O, Vuolteenaho O, et al.: Block of stretch-activated atrial natriuretic peptide secretion by gadolinium in isolated rat atrium. J Physiol. 1994; 480: 553-561.

152 Laine M, Weckstrom M, Vuolteenaho O, et al.: Effect of ryanodine on atrial natriuretic peptide secretion by contracting quiescent rat atrium. Pflug Arch Eur J Physiol. 1994; 426: 276-283.

153 Katoh S, Toyama J, Aoyama M, et al.: Mechanisms of atrial natriuretic peptide (ANP) secretion by rat hearts perfused in vitro-Ca2(+)-dependent signal transduction for ANP release by mechanical stretch. Jpn Circ J. 1990; 54: 1283-1294.

154 Kuroski-de Bold ML, de Bold AJ: Stretch-secretion coupling in atrial cardiocytes. Dissociation between atrial natriuretic factor release and mechanical activity. Hypertension. 18(Suppl.III): 169-178.

155 McDonough PM, Glembotski CC: Induction of atrial natriuretic factor and myosin light chain-2 gene expression in cultured ventricular myocytes by electrical stimulation of contraction. J Biol Chem. 1992; 267: 11665-11668.

156 Gardner DG, Wirtz H, Dobbs LG: Stretch-dependent regulation of atrial peptide synthesis and secretion in cultured atrial cardiomyocytes. Am J Physiol. 1992; 263: E239-E244.

157 Ambler SK, Leite MF: Regulation of atrial natriuretic peptide secretion by alpha 1-adrenergic receptors: the role of different second messenger pathways. J Mol Cell Cardiol. 1994; 26: 391-402.

158 Wu SQ, Kwan CY, Tang F: The effect of aging on ANP levels in the plasma, heart, and brain of rats. J Gerontol Ser A. 1997; 52 : B250-B254.

159 Kinnunen P, Vuolteenaho O, Ruskoaho H: Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993; 132: 1961-1970.

160 Schiebinger RJ, Greening KM: Interaction between stretch and hormonally stimulated atrial natriuretic peptide secretion. Am J Physiol. 1992; 262: H78-H83.

161 Skvorak JP, Nazian SJ, Dietz JR: Endothelin acts as a paracrine regulator of stretch-induced atrial natriuretic peptide release. Am J Physiol. 1995; 269: R1093-R1098.

162 Skvorak JP, Dietz JR: Endothelin and nitric oxide interact to regulate stretch induced ANP-Secretion. Am J Physiol. 1997; 273: R301-R306.

163 Ruskoaho H, Vakkuri O, Arjamaa O, et al.: Pressor hormones regulate atrial-stretch-induced release of atrial natriuretic peptide in the pithed rats. Circ Res. 1989; 64: 482-492.

164 Thibault G, Doubell AF, Garcia R, et al.: Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors. Circ Res. 1994; 74: 460-470.

165 Irons CE, Murray SF, Glembotski CC: Identification of the receptor subtype responsible for endothelin-mediated protein kinase C activation and atrial natriuretic factor secretion from atrial myocytes. J Biol Chem. 1993; 268: 23417-23421.

166 Leite MF, Page E, Ambler SK: Regulation of ANP secretion by endothelin-1 in cultured atrial myocytes: desensitization and receptor subtype. Am J Physiol. 1994. 267: H2193-H2203.

167 Schiebinger RJ, Gomez-Sanchez CE: Endothelin: a potent stimulus of atrial natriuretic peptide secretion by superfused rat atria and its dependency on calcium. Endocrinology. 1990; 127: 119-125.

168 Sei CA, Glembotski CC: Calcium dependence of phenylephrine-, endothelin-, and potassium chloride-stimulated atrial natriuretic factor secretion from long term primary neonatal rat atrial cardiocytes. J Biol Chem. 1990; 265: 7166-7172.

169 Fukuda Y, Hirata Y, Yoshimi H, et al.: Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun. 1988; 155: 167-172.

170 Lew RA, Baertschi AJ: Endothelium-dependent ANF secretion in vitro. Am J Physiol. 1992; 263: H1071-H1077.

171 Irons CE, Sei CA, Hidaka H, et al.: Proteinkinase C and calmodulin kinase are required for endothelin-stimulated atrial natriuretic factor secretion from primary atrial myocytes. J Biol Chem. 1992; 267: 5211-5216.

172 Gardner DG, Newman ED, Nakamura KK, et al.: Endothelin increases the synthesis and secretion of atrial natriuretic peptide in neonatal rat cardiocytes. Am J Physiol. 1991; 261: E177-E182.

173 Pitkanen M, Mantymaa P, Ruskoaho H: Staurosporine, a protein kinase C inhibitor, inhibits atrial natriuretic peptide secretion induced by sarafotoxin, endothelin and phorbol ester. Eur J Pharmacol. 1991; 195: 307-315.

174 Schiebinger RJ, Parr HG, Cragoe EJ Jr: Calcium: its role in alpha 1-adrenergic stimulation of atrial natriuretic peptide secretion. Endocrinology. 1992; 130: 1017-1023.

175 Lachance D, Garcia R, Gutkowska J, et al.: Mechanisms of release of atrial natriuretic factor. I. Effect of several agonists and steroids on its release by atrial minces. Biochem Biophys Res Commun. 1986; 135: 1090-1098.

176 Van de Bent V, Church DJ, Vallotton MB, et al.: [Ca2+] i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. Am J Physiol. 1994; 266: H597-H605.

177 Matsubara H, Hirata Y, Yoshimi H, et al. Role of calcium and protein kinase C in ANP secretion by cultured rat cardiocytes. Am J Physiol. 1988; 255: H504-H509.

178 Soualmia H, Barthelemy C, Masson F, et al.: Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue. J Cardiovasc Pharmacol. 1997; 29: 605-611.

179 Soualmia H, Masson F, Barthelemy C, et al.: Cellular mechanism of angiotensin II-induced atrial natriuretic peptide release in rat right atrial tissue. Life Sci. 1996; 58: 1621-1629.

180 Shubeita HE, Martinson EA, Van Bilsen M, et al.: Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by proteinkinase C in neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1992; 89: 1305-1309.

181 Bogoyevitch MA, Glennon PE, Sugden PH: Endothelin-1, phorbol esters and phenylephrine stimulate MAP kinase activity in ventricular cardiomyocytes. FEBS Lett. 1993; 317: 271-275.

182 Zongazo MA, Carayon MA, Masson F, et al.: Effects of arginine vasopressin and extracellular osmolarity on atrial natriuretic peptide release by superfused rat atria. Eur J Pharmacol. 1991; 209: 45-55.

183 Azizi C, Carayon A, Masson F, et al.: Mechanisms of isoproterenol-induced atrial natriuretic peptide release from superfused rabbit atria. Am J Physiol. 1993; 265: H1283-H1288.

184 Church DJ, Van der Bent V, Vallotton MB, et al.: Role of prostaglandin-mediated cyclic AMP formation in protein kinase C-dependent secretion of atrial natriuretic peptide in rat cardiomyocytes. Biochem J. 1994; 303: 217-225.

185 Leskinen H, Vuolteenaho O, Leppaluoto J, et al.: Role of nitric oxide on cardiac hormone secretion: Effect of N(G)-Nitro-L-arginine methyl ester on atrial natriuretic peptide and brain natriuretic peptide release. Endocrinology. 1995; 136: 1241-1249.

Melo LG, Sonnenberg H: Effect of nitric oxide inhibition on secretion of atrial natriuretic factor in isolated rat heart. Am J Physiol. 1996; 270: H306-H311.

187 Sato A, Canny BJ, Autelitano DJ: Adrenomedullin stimulates cAMP accumulation and inhibits atrial natriuretic peptide gene expression in cardiomyocytes. Biochem Biophys Res Commun. 1997; 230: 311-314.

188 Winters CJ, Sallman AL, Baker BJ, et al.: The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation. 1989; 80: 438-449.

189 Daggubati S, Parks JR, Overton RM, et al.: Adrenomedullin, endothelin, neuropeptide Y., atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res. 1997; 36: 246-255.

190 Hall C, Rouleau JL, Moye L, et al.: N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994; 89: 1934-1942.

191 Lerman A, Gibbons RJ, Rodeheffer et al.: Circulating N-terminal atrial natriuretic paptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993; 341: 1105-1109.

192 Ruskoaho H: Cardiac hormones as diagnostic tools in heart failure. Endocrine Reviews. 2003; 24: 341-356.

193 Morita H, Tanaka I, Oda T, et al.: Atrial natriuretic peptide messenger RNA and peptide in rats with aortic valve insufficiency. Peptides. 1990; 11(4): 843-847.

194 Cantin M, Thibault G, Ding JF, et al.: ANF in experimental congestive heart failure. Am J Pathol. 1988; 130: 552-568.

195 Wong NL, Wong EF, Hu DC: Atrial natriuretic factor release in cardiomyopathic hamsters. Cardiology. 1992; 80: 12-17.

196 Tsuchimochi H, Yazaki Y, Ohno H, et al.: Ventricular expression of atrial natriuretic peptide. Lancet. 1987; 2: 336-337.

197 Thibault G, Nemer M, Drouin J, et al.: Ventricles as a major site of atrial natriuretic factor synthesis and release in cardiomyopathic hamster with heart failure. Circ Res. 1989; 65: 71-82.

198 Takahashi T, Allen PD, Izumo S: Expression of A-, B-, C-type natriuretic peptide genes in failing and developing human ventricles: correlation with expression of the Ca2+-ATPase gene. Circ Res. 1992; 71: 9-17.

199 Feldman AM, Ray PE, Silan CM, et al.: Selective gene expression in failing human heart. Circulation. 1991; 83: 1866-1872.

200 Saito Y, Nakao K, Arai H, et al.: Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest. 1989; 83: 298-305.

201 Biollaz J, Callahan LT, Nussberger J, et al.: Pharmacokinetics of synthetic atrial natri>uretic peptides in normal men. Clin Pharmacol Ther. 1987; 41: 671-677.

202 Charles CJ, Espiner EA, Nicholls MG, et al.: Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996; 271: R373-R380.

203 Garcia R, Diebold S: Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 1990; 24: 430-432.

204 Langenickel T, Pagel I, Buttgereit J, et al.: Rat corin gene: Molecular cloning and reduced expression in experimental heart failure. Am J Physiol Heart Circ Physiol. 2004; 287(4): H1516-H1521.

205 Redfield MM, Edwards BS, McGoon MD, et al.: Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation. 1989; 80(3): 651-657.

206 Tomanek RJ, Torry RJ: Growth of the coronary vasculature in hypertrophy: mechanisms and model dependence. Cell Mol Biol Res. 1994; 40: 129-136.

207 Scriven TA, Burnett Jr JC: Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation. 1985; 72: 892-897.

208 Cody RJ, Atlas SA, Laragh JH, et al.: Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986; 78: 1362-1374.

209 Potter LR, Garbers DL: Protein kinase C-dependent desentization of the atrial natriuretic peptide receptor is mediated by dephosphorylation. J Biol Chem. 1994; 269: 14636-14642.

210 Volpe M, Tritto C, DeLuca N, et al.:Failure of Atrial Natriuretic Factor to Increase with Saline Load in Patients with Dilated Cardiomyopathy and Mild Heart Failure. J Clin Invest. 1991; 88: 1481-1489.

211 Volpe M, Tritto C, DeLuca N, et al.: Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. Circulation. 1992; 86(6): 1800-1809.

212 Sata N, Tanaka Y, Suzuki S, et al.: Effectiveness of Angiotensin-Converting Enyzme Inhibitor or Angiotensin II Receptor Blocker on Atrial Natriuretic Peptide. Circ J. 2003; 67: 1053-1058.

213 Tran KL, Lu X, Lei M, et al.: Up-regulation of Corin Gene Expression in Hypertrophic Cardiomyocytes and Failing Myocardium.Am J Physiol Heart Circ Physiol. 2004; 287(4): H1625-H1631.

214 Drexler H, Hanze J, Finckh M, et al.: Atrial natriuretic peptide in a rat model of cardiac failure. Atrial and ventricular mRNA, atrial content, plasma levels, and effect of volume loading. >Circulation. 1989; 79(3): 620-633.

215 Mendez RE, Pfeffer JM, Ortola FV, et al.: Atrial natriuretic peptide transcription, storage, and release in rats with myocardial infarction. Am J Physiol. 1987; 253(6Pt2): H1449-H1455.

216 Linzbach AJ: Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1960; 5: 370-382.

217 Fujiwara T, Fujiwara H, Takemura G, et al.: Expression and distribution of atrial natriuretic polypeptide in the ventricles of children with myocarditis and/or myocardial infarction secondary to Kawasaki disease: immunohistochemical study. Am Heart J. 1990; 120: 612-618.

218 Takemura G, Fujiwara H, Mukoyama M, et al.: Expression and distribution of atrial natriuretic peptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy. Circulation. 1991; 83: 181-190.

219 Currie MG, Oehlenschlager WF, Kurtz DT: Profound elevation of ventricular and pulmonary atriopeptin in a model of heart failure. Biochem Biophys Res Commun. 1987; 148(3): 1158-1164.

Edwards BS, Ackermann DM, Lee M, et al.: Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest. 1988; 81: 82-87.

221 Franch HA, Dixon RA, Blaine EH, et al.: Ventricular atrial natriuretic factor in the cardiomyopathic hamster model of congestive heart failure. Circ Res. 1988; 62: 31-36.

222 Tune JD, Richmond KN, Gorman MW, et al.: Control of coronary blood flow during exercise. Exp Biol Med. 2002; 227(4): 238-250.

223 Larsen TH, Myking O, Lillehaug Jr, et al.: Inhibition and down regulation of protein kinase C in cultured atrial myocytes: effects on distribution of specific granules and secretion of atrial natriuretic peptide. Mol Cell Endocrinol. 1993; 94:173-81.

224 Rodriquez-Pena A, Rozengurt E: Disappearance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells. Biochem Biophys Res Commun. 1984; 120(3): 1053-1059.

225 Ballester R, Rosen OM: Fate of immunoprecipitable protein kinase C in GH3 cells treated with phorbol 12-myristate 13-acetate. J Biol Chem. 1985; 260(28): 15194-15199.

226 Hepler JR, Earp HS, Harden TK: Long-term phorbol ester treatment downregulates protein kinase C and sensitizes the phosphoinositide signaling pathway to hormone and growth factor stimulation. Evidence for a role of protein kinase C in agonist induced desensitization. J Biol Chem. 188 2; 63(16): 7610-7619.

227 Pfeilschifter J, Ochsner M, Whitebread S, et al.: Down-regulation of protein kinase C potentiates angiotensin II-stimulated polyphosphoinositide hydrolysis in vascular smooth-muscle cells. Biochem J. 1989; 262(1): 285-291.

228 Kumar R, Cartledge WA, Lincoln TM, et al.: Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor blocks the activation of protein kinase C in vascular smooth muscle cells. Hypertension. 1997; 29(part 2): 414-421.

229 Uusimaa P, Ruskoaho H, Leppaluoto J, et al.: Cytosolic Ca2+ during atrial natriuretic peptide secretion from cultured neonatal cardiomyocytes. Mol Cell Endocrinol. 1990; 73: 253-263.

230 Ruskoaho H, Toth M, Ganten D, et al.: The phorbol ester induced atrial natriuretic peptide secretion is stimulated by forskolin and BAY K8644 and inhibited by 8-bromo-cyclicGMP. Biochem Biophys Res Commun. 1986; 139(1): 266-274.

231 Ruskoaho H, Vuolteenaho O, Leppäluoto J: Phorbol esters enhance stretch-induced atrial natriuretic peptide secretion. Endocrinology. 1990; 127: 2445-2455.

232 Leskinen H, Vuolteenaho O, Toth M, et al.: Atrial natriuretic peptide (ANP) inhibits its own secretion via ANP_A receptors: altered effect in experimental hypertension. Endocrinology. 1997; 138(5): 1893-1902.

233 van Bibber R, Traub O, Kroll K, et al.: EDRF and norepinephrine-induced vasodilation in the canine coronary circulation. Am J Physiol. 1995; 268(Heart Circ Physiol 37): H1973-H1981.

234 Hirata K-I, Kuroda R, Sakoda T, et al.: Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension. 1995; 25: 180-185.

235 Church DJ, Braconi S, Van der Bent V, et al.: Protein kinase C-dependent prostaglandin production mediates angiotensin II-induced atrial-natriuretic peptide release. Biochem J. 1994; 298: 451-456.

236 Ruskoaho H: Atrial Natriuretic Peptide: Synthesis, Release, and Metabolism. Pharmacological Reviews. 1992; 44(4):479-602.

237 Willenbrock R, Scheuermann M, Thibault G, et al.: Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt. Cardiovasc Res. 1999; 42: 733-742.

238 Qing G, Garcia R: Characterization of plasma and tissue atrial natriuretic factor during development of moderate high output heart failure in the rat. Cardiovasc Res. 1993; 27: 464-470.

239 Garcia R, Lachance D, Thibault G: Atrial natriuretic factor release and natriuresis in rats with high-output heart failure. Am J Physiol. 1990; 259(5Pt2): H1374-H1379.

240 Langenickel T, Pagel I, Höhnel K, et al.: Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol. 2000; 278: H1500-H1506.

241 Brown LA, Nunez D, Wilkins MR: Differential Regulation of Natriuretic Peptide Receptor Messenger RNAs during the Development of Cardiac Hypertrophy in the Rat. J Clin Invest. 1993; 92: 2702-2712.

242 Forssmann WG, Richter R, Meyer M: The endocrine heart and natriuretic peptides: histochemistry cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol. 1998; 110:335-357.

243 Zink R, Heiny o, Steiert H: Bedienungsanleitung zur Apparatur isoliertes Herz Größe 3, Typ 830, Version 1.0. 1994; 16.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
26.10.2005